Biotech Industry · us
Delivering RNA Therapies to Muscle and the Heart: Soufflé Raises $135 Million to Advance Clinical Development
Soufflé uses cell receptors as entry points for delivery and is preparing to move three oligonucleotide therapies targeting tissues beyond the liver into human studies. The new funding supports its development plans, while efficacy and safety remain to be validated in clinical trials.
Getting RNA therapies into specific cells is a hurdle in translating molecular design into treatment. Soufflé Therapeutics is focusing on tissues beyond the liver, particularly skeletal and cardiac muscle. On October 13, 2026, the company announced the completion of a $135 million Series B financing to support the advancement of three lead programs toward clinical studies.
The round was led by Juvia Group, and the company said it was oversubscribed. Participating investor Safar Partners also reposted the announcement, confirming that the funding would support the three programs and pipeline expansion into other cells and tissues. Separately, an S&P Capital IQ transaction report published by MarketScreener stated that convertible preferred shares were issued in the financing. The announcement did not disclose the company's valuation or funding allocations for individual programs.
Soufflé's core platform, REMEDY, uses receptor-mediated delivery: it first identifies receptors that allow cells to internalize conjugates, then designs proprietary monoclonal antibodies or other ligands to guide oligonucleotide therapies to specific cells. The strategy centers on establishing delivery pathways through cellular recognition mechanisms. Whether it can achieve sufficient and sustained activity in humans remains a question for subsequent studies.
The most advanced program targets facioscapulohumeral muscular dystrophy (FSHD), with delivery directed to striated muscle. The second program targets the PLN gene in cardiomyocytes and is being developed for heart failure with reduced ejection fraction (HFrEF). These two programs bring the same delivery platform to the respective development requirements of skeletal and cardiac muscle, and will also test its applicability across cell types.
The third program addresses muscle and metabolic diseases, but its molecular target has not yet been disclosed. The company also plans to expand into other cells and tissues. However, this announcement did not disclose the delivery receptors used, drug candidate codes, or quantitative delivery data, leaving insufficient information to compare the technological maturity of the individual programs.
The financing gives Soufflé resources to advance its initial clinical development, but cannot yet be regarded as human validation of the platform. The announcement did not provide trial start dates, enrollment sizes, dosing schedules, or human safety data, and the content from Safar Partners also came from the same company announcement. The next key question is whether clinical studies can translate the cell-selective design into measurable drug activity and patient benefit.